A Study of LY4060874 in Healthy Participants

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4060874 in Healthy Participants

The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants.

Study participation may last up to 22 weeks and up to approximately 18 study visits.

Inclusion Criteria:

• Are overtly healthy as determined by medical evaluation, including medical history and physical examination.
• Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m²), inclusive, at screening.
• To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China.
• To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participants' biological grandparents must be of exclusive Japanese descent and born in Japan.

Exclusion Criteria:

• Have a history of or have been diagnosed with Type 1 or Type 2 diabetes mellitus.
• Have hemoglobin A1c (HbA1c) > 6.4% or 46 millimoles/mole (mmol/mol) at screening.
• Have taken approved, including over the counter (OTC) or prescribed, medication or investigational medication for weight loss, including GLP-1 receptor agonists, within the previous 3 months of study screening.
• Have had surgical treatment for obesity.
• Are actively participating in a weight loss program or intend to initiate an intensive diet and/or exercise program during the study.